top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

DNA/RNA synthesis Market Update Prospects and Growth Assessment

0 votes
3 views

Transparency Market Research (TMR) observes that the global oligonucleotide synthesis market has a highly competitive vendor landscape. Key players such as Thermo Fisher Scientific, DNA Technologies, GE Healthcare, BioAutomation, and Applied Biosystems are operating in the global oligonucleotide synthesis market. The stiff competition in the market is resulting in a high level of competition in the market, which is likely to increase treat for entrants in the market. In order to account for a substantial share in the global market and attract customers, the key players are cutting down prices.

According to the report by Transparency Market Research, the oligonucleotide synthesis market stood at US$1.65 bn in 2016 and is projected to reach a value of US$4.189 bn by the end of 2025. The market is likely to expand with a stellar CAGR of 11.2% over the forecast period from 2017 and 2025.

Based on the type, the synthesis oligonucleotides segment is expected to register the highest growth in the coming future owing to the high preference of pharmaceutical, research and diagnostics in the biotechnology sector. Based on the end user, the research institute segment is accounting for leading share over the forecast period. Based on the region, North America dominated the global oligonucleotides synthesis market and likely to dominate the market over the forecast period. However, Asia Pacific is likely to witness growth by clocking a healthy CAGR of 12.5% between 2017 and 2025. Of these, China is a major driver for growth in the region on the back of growing adoption from home to numerous small companies.

Growing Adoption of Genetic Testing to Propel Market Growth

The oligonucleotide synthesis market is gaining traction due to the declining cost of sequencing which is resulting in the customized nucleotides for the desired sequence across research and drug development. Additionally, the growing adoption of the oligonucleotide from genetic testing and forensic applications across various life science industries is propelling the growth of the global oligonucleotide synthesis market.

Oligonucleotide synthesis has a key role in several ongoing genetic research studies. Rising investments in genetic research are boosting demand for custom synthesis. The oligonucleotide synthesis is used for the manufacture of different classes of oligos such as decoys, immunostimulatory, aptamers, antisense, miRNA, and siRNA. Widening application of the oligonucleotide synthesis is propelling the growth of the global oligonucleotide synthesis market.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=11804

Growing Approvals for Pipeline Drugs to Propel Market Growth

The largest share of the oligonucleotides is used across the phase clinical trials for targeting various diseases such as cancer, muscle dystrophies, cardiovascular diseases, and ocular disorders. Growing regulatory approvals on the multiple therapies especially based on the oligonucleotide are expected to drive the growth of the global oligonucleotide synthesis market.

Marketing focus and adoption of advanced strategies, which include enhancing direct selling, and distributors in specific countries especially developing countries. Additionally, benefits of the oligonucleotides and growing its synthesis are propelling the growth of the global oligonucleotides synthesis market.

More Trending Reports by Transparency Market Research –

Surgical Robots Market: https://www.prnewswire.com/news-releases/surgical-robots-market-to-reach-us13-1-bn-by-2027-as-acceptance-jumps-high-in-emerging-regions-tmr-study-300997542.html

Arthritis Therapeutics Market: https://www.prnewswire.com/news-releases/global-arthritis-therapeutics-market-to-grow-at-over-6-annually-to-reach-usd-72-billion-valuation-by-2027-transparency-market-research-300997527.html

posted 6 days ago by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Partial Onset Seizures Market: Introduction

  • Partial onset seizure occurs due to abnormal electrical activity in one part of the brain. It is also known as focal seizure. Focal seizures can be of two types: focal seizure without loss of consciousness and focal seizure with impaired awareness. Focal seizure without loss of consciousness is known as simple partial seizure, while focal seizure with impaired awareness is known as complex partial seizure.
  • A seizure is a transient disruption of brain function due to abnormal and excessive electrical discharges in brain cells. According to the American Epilepsy Society, around 14% of individuals suffers from simple partial seizure, while 36% individuals with epilepsy have complex partial seizure.

Report Overview @ https://www.transparencymarketresearch.com/partial-onset-seizures-market.html

Key Drivers of Global Partial Onset Seizures Market

  • The global partial onset seizures market is projected to be driven by rise in prevalence of epilepsy. Incidence of epilepsy is higher in developing countries due to late diagnosis and availability of necessary health care and treatment facilities. Therefore, rise in prevalence of epilepsy is anticipated to drive the global partial onset seizures market.
  • According to the Epilepsy Society, epilepsy is the fourth most common type of neurological problem. Around 87 individuals are diagnosed with epilepsy every day, while 60 million people across the world are living with epilepsy.
  • Increase in research activities drives the global partial onset seizures market. Moreover, a large number of new antiepileptic drugs are in development with novel mode of action. This, in turn, is expected to contribute to the growth of the global partial onset seizures market during the forecast period.
  • Increase in public awareness and introduction of educational programs in several countries in the past few years are likely to propel the global partial onset seizures market during the forecast period. Moreover, wider approval of marijuana-based drugs by the FDA for partial onset seizure treatment is projected to propel the global partial onset seizures market.

Request PDF Sample of Partial Onset Seizures Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=75401

North America to Account for Significant Share of Global Partial Onset Seizures Market

  • North America is a major market for partial onset seizures because of presence of leading pharmaceutical players and their well-established research & development infrastructure
  • According to the Epilepsy Foundation, an estimated 150,000 incidences of epilepsy occur in the U.S. each year
  • Europe was the second leading market due to large number of extensive drug development & formulation based research projects and high awareness & importance among the people about health
  • Growth of the market in North America and Europe is attributed to high per capita income of individuals in major developed countries in these regions. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period because of rise in prevalence of partial onset seizure and initiatives by governments of developing countries to improve overall health of the people.

Pre Book “Partial Onset Seizures Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=75401&ltype=S

Key Players Operating in Global Partial Onset Seizures Market

Major players in the global partial onset seizures market are:

  • Mylan N.V.
  • Novartis AG
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Abbott Laboratories

More Trending Reports by Transparency Market Research –

Medical Image Analysis Software Market: prnewswire.com/news-releases/medical-image-analysis-software-market-to-obtain-a-valuation-of-us-4-6-bn-by-2024-says-tmr-836666587.html

Pharmerging Market: prnewswire.com/news-releases/pharmerging-market-to-hit-us1-40-billion-by-2024—says-tmr-300800262.html

0 votes

The demand within the global market for intraocular lenses has been rising on account of the rising cases of cataract across the world, finds Transparency Market Research (TMR). The market vendors in the global intraocular lenses market have been making ardent effort to provide seamless services to the consumers. Intraocular lenses are used during cataract surgeries, and hence, it is immensely important to ensure high standards of production and quality. The market vendors in the global intraocular lenses market have taken an onus upon themselves to produce high quality lenses. Furthermore, these vendors have formed alliances with manufacturers of other eye-treatment products in recent times.

It is expected that the leading vendors in the global intraocular lenses market would capitalise on improving the quality of their lenses. Moreover, acquisition of smaller sellers of intraocular lenses is also expected to be a key strategy for the key vendors. The small-scale vendors in the global intraocular lenses market are concentrating on facilitating technology transfer from established vendors. These small vendors in the global intraocular lenses market are also expected to form alliance in order to sustain in the market. Some of the key vendors in the global intraocular lenses market are Alcon, Bausch & Lomb, Inc, Johnson & Johnson Vision Care, and Abbott Medical Optics.

Request PDF Sample of Intraocular Lens Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2170

Transparency Market Research (TMR) predicts that the global intraocular lenses market would expand at a steady CAGR of 5.20% during period between 2017 and 2024. Furthermore, the global market for intraocular lenses would reach a value of US$5069.5 mn by the end of 2024, rising up from a value of US$3553.4 mn in 2016. On the basis of geography, the market for intraocular lenses is projected to expand at a stellar pace in North America.

Availability of Advanced Treatment Facilities to Propel

The demand within the global market for intraocular lenses has been rising on account of the rising incidence of retinal disorders. Furthermore, the past decade has witnessed key advancements in the domain of ophthalmology, and several new treatment mechanisms and technologies have come to the fore. This factor has also played a crucial role in the growth of global intraocular lenses market in recent times. There is a high possibility of new growth avenues emerging in the global intraocular lenses market as people become more concerned about eye care. The market for intraocular lenses shall also reap in voluminous revenues as skilled doctors and specialists make their way into the global healthcare fraternity.

Buy Now “Intraocular Lens Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2170&ltype=S

Unfavourable Reimbursement Policies could hamper Market Growth

The global market for intraocular lenses has been expanding at starry pace, but a number of trends could hinder market growth. Medical reimbursement policies across a number of regions exclude eye care or ophthalmology treatments. This factor could be a severe roadblock for the growth of the global intraocular lenses market. However, the decreasing prices of cataract surgeries and treatments would continue attract new consumers into the market. Moreover, promotional campaigns for eye care treatments have also emerged as a key prospect for the growth of the global intraocular lenses market.

0 votes

The fertility testing devices market is poised to register significant growth with 5% CAGR during 2018 and 2026. The market was evaluated at US$420 mn, its highest in 2017. The market is expected to reach $600 mn by 2026. The market is projected to witness robust growth as technological advancements drives demand for portable, quick, and accurate testing.

Additionally, high prevalence of chronic and lifestyle illnesses like cancers, and diabetes are also expected to result in tremendous demand for advanced medical devices in the near future. Growing liberalization of sexual activity, and arising issues like teenage pregnancy are expected to make way for home-based testing methods. To supplement this growth, the technological advancements like electrical devices, fertility prediction kits, and sperm test kits are on the rise. Factors such as lack of exercise, rising stress in work life, and delayed pregnancy trends among women are also expected to drive significant growth for fertility and sperm monitoring devices.

Request PDF Sample of Fertility Testing Devices Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18689

Rise in Fertility Rates a Major Reason for Growth

Rising disposable incomes and rising birth rates across the globes are expected to drive significant growth for the fertility testing devices market. Additionally lifestyle diseases like diabetes, and rising economic instability are hindrance in some regions. The growth in child rates and rising awareness about fertility rates in developed regions are expected to major drivers of growth. Additionally, rise of startups and online portals are raising awareness about sexual health. Moreover, increasing initiatives by private companies to cater to young women who work late are also expected to drive significant growth for the market. Among these are companies like Facebook, and Google who announced that they were looking at ways to provide options to women to freeze their eggs for production at later stages in life. The rising support in the private sector for working women is likely to drive significant growth for the fertility testing devices market.

Ovulation Monitoring Devices Promise Robust Growth

Based on product type, the global fertility testing devices market is divided into distribution channel, gender, and region. Among various products in the market, the prominent ones include fertility monitors, ovulation prediction kits, male fertility testing kits, and other. Additionally, products like urine-based monitors, and saliva-based monitors are also prominent in the market. Among these, the saliva-based monitors are growing in demand as a non-invasive clean, and reusable technology. The ovulation prediction kit are expected to emerge as the largest in the near future as it has conventionally held the largest share of the market. These kits also provide an easy-to-use applications, and widely available.

Enquiry for Discount on “Fertility Testing Devices Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=18689

High costs of the devices and rising competition for a small number of application is expected to remain a hindrance to growth for the fertility testing devices market. However, rising birth rates in non-Caucasians are expected to result in significant growth.

Some key players having significant presence in the global fertility testing devices market are engaging in geographic expansion, and technological developments in order to gain significant strategic advantage in the global landscape. Major players operating in the global fertility testing devices market include Geratherm Medical AG, bioZhena Corporation, SPD Swiss Precision Diagnostics GmbH, Alfa Scientific Designs, Inc., Ava Science Inc., Piramal Enterprises Ltd, Emay (HK) Limited, and Hilin Life Products.

0 votes

Some of the prominent players operating in the global hemophilia treatment drugs market are Pfizer, Inc., Kedrion, Shire Plc., CSL Behring, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Bayer AG,  and Sanofi, finds Transparncy Market Reseach(TMR).

These players are adopting several strategies such as mergers and acquisitions, business expansions and collaborations in order to fortify their market positions. On January 8, 2019, Takeda Pharmaceutical Company Limited acquired Shire plc, prominent players in the hemophilia treatment drugs market. This accusation has made Takeda Pharmaceutical Company Limited a value based R&D-driven biopharmaceutical leader in Japan.

According to TMR, the global hemophilia treatment drugs market was noted at a valuation of  US$ 10,000.0mn in 2017.  Owing to increasing FDA approval to new patents, the market is expected to rise at a CAGR of 5.0% from 2018 to 2026.On the basis of geography, North America is expected to dominate the global hemophilia treatment drugs market in the coming years. This is mainly due to increasing awareness of advanced treatment technologies among patients about the condition.  On the basis of product type, the recombinant coagulation factor concentrates segment is expected to dominate the hemophilia treatment drugs market during the forecast period.  Factors such as superior reproducibility of these products, as compared to others are increasing the demand. Apart from this, innovative product launches based on the segment by manufacturers is fueling the growth.

Request PDF Sample of Hemophilia Treatment Drugs Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1900

Favorable Governmental Polices to Drive Market

The global hemophila treatment market is expected to expand at a significant pace during the forecast period. This is mainly because of the rising demand for effective treatment of hemophila. Owing to this, regulatory authorities are spending a hefty amount for the development of advanced drugs for the treatment of these disorders. This, in turn, is expected to boost growth during the forecast period.

Furthermore, surge in campaigns by non profitable organizations and supportive governmental initiatives to spread awareness among the patients to undertake early screening of neonates. This is another strong factor which is expected to propel hemophilia treatment drugs market.

Hemophilia is a rare genetic bleeding disorder estimated to have affected about 440,000 people globally as of 2018. The federation also mentions that about 75.0% of these individuals are either undiagnosed or receive inappropriate treatment. These figures are alarming and clearly depict need for many more awareness program by the private and public authorities.

Enquiry for Discount on “Hemophilia Treatment Drugs Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1900

High Costs of Treatment to Hamper Prospects

On the flipside, high costs of the hemophilia treatment drugs is one factor expected to impede growth in the global hemophilla treatment drugs market.

One noteworthy tread prevailing treatment drugs market is initiative taken by agencies such as the Hemophilia Association of America to cut down cost of diseases.  This is expected to neutralize offer new possibilities to growth of the hemophilla market. For instance, CSL Behring, a players in the healthcare industry  allocated1.5 million to its antihemophilic unit  on the occasion of World Hemophilia Day (April 17).

Further, increase in number of patent by the FDA for the efficient treatment of the hemophilla is expected to offer several opportunities in the hemophilla treatment drugs market. Several new and existing players are launching drugs based on this patient to offer effective treating hemophilia. This is another factor expected to propel the hemophilla treatment drugs market in the coming years.

0 votes

Some of the prominent players operating in the global hemophilia treatment drugs market are Pfizer, Inc., Kedrion, Shire Plc., CSL Behring, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Bayer AG,  and Sanofi, finds Transparncy Market Reseach(TMR).

These players are adopting several strategies such as mergers and acquisitions, business expansions and collaborations in order to fortify their market positions. On January 8, 2019, Takeda Pharmaceutical Company Limited acquired Shire plc, prominent players in the hemophilia treatment drugs market. This accusation has made Takeda Pharmaceutical Company Limited a value based R&D-driven biopharmaceutical leader in Japan.

According to TMR, the global hemophilia treatment drugs market was noted at a valuation of  US$ 10,000.0mn in 2017.  Owing to increasing FDA approval to new patents, the market is expected to rise at a CAGR of 5.0% from 2018 to 2026.

On the basis of geography, North America is expected to dominate the global hemophilia treatment drugs market in the coming years. This is mainly due to increasing awareness of advanced treatment technologies among patients about the condition.  On the basis of product type, the recombinant coagulation factor concentrates segment is expected to dominate the hemophilia treatment drugs market during the forecast period.  Factors such as superior reproducibility of these products, as compared to others are increasing the demand. Apart from this, innovative product launches based on the segment by manufacturers is fueling the growth.

Request PDF Sample of Hemophilia Treatment Drugs Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1900

Favorable Governmental Polices to Drive Market

The global hemophila treatment market is expected to expand at a significant pace during the forecast period. This is mainly because of the rising demand for effective treatment of hemophila. Owing to this, regulatory authorities are spending a hefty amount for the development of advanced drugs for the treatment of these disorders. This, in turn, is expected to boost growth during the forecast period.

Furthermore, surge in campaigns by non profitable organizations and supportive governmental initiatives to spread awareness among the patients to undertake early screening of neonates. This is another strong factor which is expected to propel hemophilia treatment drugs market.

Hemophilia is a rare genetic bleeding disorder estimated to have affected about 440,000 people globally as of 2018. The federation also mentions that about 75.0% of these individuals are either undiagnosed or receive inappropriate treatment. These figures are alarming and clearly depict need for many more awareness program by the private and public authorities.

Enquiry for Discount on “Hemophilia Treatment Drugs Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1900

High Costs of Treatment to Hamper Prospects

On the flipside, high costs of the hemophilia treatment drugs is one factor expected to impede growth in the global hemophilla treatment drugs market.

One noteworthy tread prevailing treatment drugs market is initiative taken by agencies such as the Hemophilia Association of America to cut down cost of diseases.  This is expected to neutralize offer new possibilities to growth of the hemophilla market. For instance, CSL Behring, a players in the healthcare industry  allocated1.5 million to its antihemophilic unit  on the occasion of World Hemophilia Day (April 17).

Further, increase in number of patent by the FDA for the efficient treatment of the hemophilla is expected to offer several opportunities in the hemophilla treatment drugs market. Several new and existing players are launching drugs based on this patient to offer effective treating hemophilia. This is another factor expected to propel the hemophilla treatment drugs market in the coming years.

...